Clinical and Molecular Characteristics of Non-Transfusion-Dependent Thalassemia in Kuwait

References

• Weatherall DJ, Clegg JB. The Thalassaemia Syndromes, 4th ed. Oxford, UK: Blackwell Science, 2001
   Google Scholar
• Weatherall DJ. The definition and epidemiology of non-transfusion-dependent thalassemia. Blood Rev. 2012;26(Suppl 1):S3–S6
   PubMed Web of Science ®Google Scholar
• Galanello R. Recent advances in the molecular understanding of non-transfusion-dependent thalassemia. Blood Rev. 2012;26(Suppl 1):S7–S11
   PubMed Web of Science ®Google Scholar
• Thein SL. The emerging role of fetal hemoglobin induction in non-transfusion-dependent thalassemia. Blood Rev. 2012;26(Suppl 1):S35–S39
   PubMed Web of Science ®Google Scholar
• Higgs DR. The molecular basis of α-thalassemia. Cold Spring Harb Perspect Med. 2013;3(1):a011718. doi: 10.1101/cshperspect.a011718
   PubMed Web of Science ®Google Scholar
• Chui DHK. α-Thalassaemia and population health in Southeast Asia. Ann Hum Biol. 2005;32(2):123–130
   PubMed Web of Science ®Google Scholar
• Fucharoen S, Winichagoon P. Haemoglobinopathies in southeast Asia. Indian J Med Res. 2011;134(4):498–506
   PubMedGoogle Scholar
• Olivieri NF, Pakbaz Z, Vichinsky E. Hb E/β-thalassaemia: A common and clinically diverse disorder. Indian J Med Res. 2011;134(4):522–531
   PubMedGoogle Scholar
• Pal R, Bagchi S, Kar S, Pal S. Hb E/β0 thalassemia can present with normal phenotype. Asian J Transfus Sci. 2010;4(2):134–135
   PubMedGoogle Scholar
• Musallam KM, Cappellini MD, Wood JC, Taher AT. Iron overload in non-transfusion-dependent thalassemia: A clinical perspective. Blood Rev. 2012;26(Suppl 1):S16–S19
   PubMed Web of Science ®Google Scholar
• Taher AT, Cappellini MD, Musallam KM. Recent advances and treatment challenges in patients with non-transfusion-dependent thalassemia. Blood Rev. 2012;26(Suppl 1):S1–S2
   PubMedGoogle Scholar
• Taher AT, Porter JB, Viprakasit V, et al. Approaching low liver iron burden in chelated patients with non-transfusion-dependent thalassemia: The safety profile of deferasirox. Eur J Haematol. 2014;92(6):521–526
   PubMed Web of Science ®Google Scholar
• Matta BN, Musallam KM, Maakaron JE, et al. A killer revealed: 10-year experience with β-thalassemia intermedia. Hematology. 2014;19(4):196–198
   PubMed Web of Science ®Google Scholar
• Taher AT, Temraz S, Cappellini MD. Deferasirox for the treatment of iron overload in non-transfusion-dependent thalassemia. Expert Rev Hematol. 2013;6(5):495–509
   PubMed Web of Science ®Google Scholar
• Shammas C, Papasavva T, Felekis X, et al. ThalassoChip, an array mutation and single nucleotide polymorphism detection tool for the diagnosis of β-thalassaemia. Clin Chem Lab Med. 2010;48(12):1713–1718
   PubMed Web of Science ®Google Scholar
• Baysal E, Huisman THJ. Detection of common deletional α-thalassemia-2 determinants by PCR. Am J Hematol. 1994;46(3):208–213
   PubMed Web of Science ®Google Scholar
• Adekile AD, Haider MZ. Morbidity, βS haplotype and α-globin gene patterns among sickle cell anemia patients in Kuwait. Acta Haematol. 1996;96(3):150–154
   PubMed Web of Science ®Google Scholar
• Tanner MA, He T, Westwood MA, et al. Multi-center validation of the transferability of the magnetic resonance T2* technique for the quantification of tissue iron. Haematologica. 2006;91(10):1388–1391
   PubMed Web of Science ®Google Scholar
• Hankins JS, McCarville MB, Loeffler RB, et al. R2* magnetic resonance imaging of the liver in patients with iron overload. Blood. 2009;113(20):4853–4855
   PubMed Web of Science ®Google Scholar
• Abu-Hakima A. History of Eastern Arabia 1750-1800: The rise and development of Bahrain, Kuwait and Wahhabi Saudi Arabia. London, UK: Probsthain, 1965
   Google Scholar
• Abdulwahid DA, Hassan MK. β- And α-thalassemia intermedia in Basra, Southern Iraq. Hemoglobin. 2013;37(6):553–563
   PubMed Web of Science ®Google Scholar
• Adekile AD, Haider M, Kutlar F. Mutations associated with β-thalassemia intermedia in Kuwait. Med Princ Pract. 2005;14(Suppl 1):69–72
   PubMed Web of Science ®Google Scholar
• Al-Allawi NA, Jalal SD, Mohammad AM, et al. β-Thalassemia intermedia in Northern Iraq: A single center experience. BioMed Res Int. 2014;2014:262853. doi: 10.1155/2014/262853
   PubMed Web of Science ®Google Scholar
• Ankra-Badu GA, Al-Jama A, Al Kadim Y. Hemoglobin H disease in the Al-Qatif Region of Saudi Arabia. Ann Saudi Med. 2001;21(5–6):308–311
   PubMed Web of Science ®Google Scholar
• Haider M. Adekile AD: α2-Globin gene polyadenylation (AATAAA→AATAAG) mutation in Hemoglobin H disease among Kuwaitis. Med Princ Pract. 2005;14(Suppl 1):73–76
   PubMed Web of Science ®Google Scholar
• Wali Y, Zadjali SA, Elshinawy M, et al. Severity ranking of non-deletional α thalassemic alleles: Insights from an Omani family study. Eur J Haematol. 2011;86(6):507–511
   PubMed Web of Science ®Google Scholar
• Higgs DR, Goodbourn SE, Lamb J, et al. α-Thalassaemia caused by a polyadenylation signal mutation. Nature. 1983;306(5941):398–400
   PubMed Web of Science ®Google Scholar
• Thein SL, Wallace RB, Pressley L, et al. The polyadenylation site mutation in the α-globin gene cluster. Blood. 1988;71(2):313–319
   PubMed Web of Science ®Google Scholar
• Musallam KM, Rivella S, Vichinsky E, Rachmilewitz EA. Non-transfusion-dependent thalassemias. Haematologica. 2013;98(6):833–844
   PubMed Web of Science ®Google Scholar
• Ganz T. Hepcidin and iron regulation, 10 years later. Blood. 2011;117(17):4425–4433
   PubMed Web of Science ®Google Scholar
• Ganz T, Nemeth E. The hepcidin-ferroportin system as a therapeutic target in anemias and iron overload disorders. Hematology Am Soc Hematol Educ Program. 2011;2011:538–542. doi: 10.1182/asheducation-2011.1.538
   PubMed Web of Science ®Google Scholar
• Taher AT, Viprakasit V, Musallam KM. Cappellini MD. Treating iron overload in patients with non-transfusion-dependent thalassemia. Am J Hematol. 2013;88(5):409–415
   PubMed Web of Science ®Google Scholar
• Cappellini MD, Musallam KM, Poggiali E, Taher AT. Hypercoagulability in non-transfusion-dependent thalassemia. Blood Rev. 2012;26(1):S20–S23
   PubMedGoogle Scholar
• Karimi M, Musallam KM, Cappellini MD, et al. Risk factors for pulmonary hypertension in patients with β thalassemia intermedia. Eur J Int Med. 2011;22(6):607–610
   PubMed Web of Science ®Google Scholar
• Taher A, Isma’eel H, Mehio G, et al. Prevalence of thromboembolic events among 8,860 patients with thalassaemia major and intermedia in the Mediterranean area and Iran. Thromb Haemost. 2006;96(4):488–491
   PubMed Web of Science ®Google Scholar
• Musallam KM, Taher AT, Karimi M, Rachmilewitz EA. Cerebral infarction in β-thalassemia intermedia: Breaking the silence. Thromb Res. 2012;130(5):695–702
   PubMed Web of Science ®Google Scholar
• Musallam KM, Cappellini MD, Daar S, et al. Serum ferritin level and morbidity risk in transfusion-independent patients with β-thalassemia intermedia: The ORIENT study. Haematologica. 2014;99(11):e218–e221
   PubMed Web of Science ®Google Scholar
• Taher AT, Musallam KM, El-Beshlawy A, et al. Age-related complications in treatment-naive patients with thalassaemia intermedia. Br J Haematol. 2010;150(4):486–489
   PubMed Web of Science ®Google Scholar
• Cappellini MD, Musallam KM, Taher AT. Insight onto the pathophysiology and clinical complications of thalassemia intermedia. Hemoglobin. 2009;33(Suppl 1):S145–S159
   PubMedGoogle Scholar
• Taher A, Isma’eel H, Cappellini MD. Thalassemia intermedia: Revisited. Blood Cells Mol Dis. 2006;37(1):12–20
   PubMed Web of Science ®Google Scholar
• Au WY, Cheung WC, Hu WH, et al. Hyperbilirubinemia and cholelithiasis in Chinese patients with Hemoglobin H disease. Ann Hematol. 2005;84(10):671–674
   PubMed Web of Science ®Google Scholar
• Premawardhena A, Fisher CA, Fathiu F, et al. Genetic determinants of jaundice and gallstones in Haemoglobin E β thalassaemia. Lancet. 2001;357(9272):1945–1946
   PubMed Web of Science ®Google Scholar
• Musallam KM, Sankaran VG, Cappellini MD, et al. Fetal hemoglobin levels and morbidity in untransfused patients with β-thalassemia intermedia. Blood. 2012;119(2):364–367
   PubMed Web of Science ®Google Scholar
• Kosaryan M, Karami H, Zafari M, Yaghobi N. Report on patients with non transfusion-dependent β-thalassemia major being treated with hydroxyurea attending the Thalassemia Research Center, Sari, Mazandaran Province, Islamic Republic of Iran in 2013. Hemoglobin. 2014;38(2):115–118
   PubMed Web of Science ®Google Scholar